Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model

Aytan H, Hakan Aytan, Caliskan AC, Ahmet C Caliskan, Ahmet Çalışkan, Demirturk F, Fazlı Demirtürk, Fazli Demirturk, Pelin Aytan, AYTAN P, Dogan R Koseoglu, Koseoglu DR, Doğan Köseoğlu
The Australian & New Zealand journal of obstetrics & gynaecology · 2007 · vol. 47(4) , pp. 321–325 · doi:10.1111/j.1479-828x.2007.00744.x · PMID:17627689 · W2094497594
Lab / animal OA: closed CC0 ⤵ 27 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Rosiglitazone treatment reduced the size of experimental endometriosis in rats, although it also negatively impacted epithelial preservation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: The effect of rosiglitazone, an activator of peroxisome proliferator-activated receptor-gamma, on the growth of ectopic uterine tissue was assessed. METHODS: Endometriosis was surgically induced in 28 rats by transplanting an autologous fragment of endometrial tissue onto the inner surface of the abdominal wall. Four weeks later, rats were randomly grouped and a second laparatomy was performed. The length, width, height and volume of the explants were measured. Rosiglitazone at 0.2 mg/kg/day was orally administered to one group, while vehicle treatment was given to the control group. Four weeks later, rats were sacrificed and ectopic uterine tissues were re-evaluated morphologically and histologically. Scoring system was used to evaluate the preservation of epithelia. RESULTS: One rat in the study group and two rats in the control group died as a result of complications related to surgery. There was a significant difference in post-treatment length, width, height, and spherical volumes between control and rosiglitazone-treated groups. The epithelia were found to be preserved significantly better in the control group when compared with the rosiglitazone-treated group. CONCLUSION: Rosiglitazone was found to cause regression of experimental endometriosis in rats.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis PPAR gamma Thiazolidinediones Animals Animals Disease Models, Animal Disease Models, Animal Endometriosis Endometriosis Endometrium Endometrium Endometrium Female Female Macrophages Macrophages Macrophages PPAR gamma PPAR gamma Rats

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (39)

Cited by (27)

Source provenance

europepmc
last seen: 2026-10-12T06:17:10.165071+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:04:31.715410+00:00
unpaywall
last seen: 2026-10-12T06:33:14.382917+00:00
License: CC0 · commercial use OK